NCT03903549View on ClinicalTrials.gov

Initial Investigation of [18F]P17-059 in Parkinson's Disease Patients and Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

December 19, 2022

Study Completion Date

December 19, 2022

Conditions
Parkinson Disease
Interventions
DRUG

[18F]P17-059

Injection of \< 10 mCi \[18F\]P17-059 followed by PET/CT scanning

Trial Locations (1)

21287

Johns Hopkins Medical Institutions, Baltimore

All Listed Sponsors
lead

Five Eleven Pharma, Inc.

INDUSTRY